Evidence map›Paper›PMID 40065412›Full record

ArticleParasites & vectors2025

Efficacy of a novel chewable tablet (Credelio Quattro

Samuel Charles, Gertraut Altreuther, Xinshuo Wang, Scott Wiseman, Craig R Reinemeyer, Daniel E Snyder, Michael Ulrich, Padraig Doherty, Lisa Young

Abstract read
In one paragraph

Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Samuel CharlesElanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA.
Gertraut AltreutherElanco Animal Health GmbH, Alfred-Nobel-Str. 50, 40789, Monheim, Germany.
Xinshuo WangElanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA.
Scott WisemanElanco Animal Health, Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA, UK.
Craig R ReinemeyerEast Tennessee Clinical Research, Inc, 80 Copper Ridge Farm Road, Rockwood, TN, 37854, USA.
Daniel E SnyderDaniel E. Snyder DVM, Ph.D. Consulting LLC, 7348 Yorkshire Blvd., Indianapolis, IN, 46229, USA.
Michael UlrichCheri-Hill Kennels, 17190 Polk Rd., Stanwood, MI, 49346, USA.
Padraig DohertyIorras Product Development Ltd., Glenamoy, Ballina Co. Mayo, Ireland.
Lisa YoungElanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA. lisa.young@elancoah.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile generally harmless to dogs, the cestode species Echinococcus granulosus and Echinococcus multilocularis have significant zoonotic importance, causing cystic echinococcosis and alveolar echinococcosis in humans, respectively. Regular deworming is essential to treat intestinal cestode infections in dogs and to reduce environmental egg contamination and thus the subsequent zoonotic risk of infection to intermediate hosts and humans. The studies described here evaluated the efficacy of a new novel chewable tablet combination containing lotilaner, moxidectin, praziquantel and pyrantel (Credelio Quattro, Elanco Animal Health) against E. granulosus and E. multilocularis infections in dogs.

methodsFour negative-controlled, masked, randomized laboratory studies were conducted. Two studies each evaluated the efficacy of Credelio Quattro at the minimum dosages of 20.0 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5.0 mg/kg praziquantel and 5.0 mg/kg pyrantel against E. granulosus (Studies 1 and 2) and E. multilocularis (Studies 3 and 4). Studies 2 and 4 also included treatment groups that received praziquantel alone or lotilaner alone, at the same minimum dosages, to assess whether lotilaner, moxidectin or pyrantel interfered with the activity of praziquantel in Credelio Quattro against these two cestode species. In Studies 1 and 3, 16 purpose-bred dogs were divided into two groups of eight, while in Studies 2 and 4, 32 dogs were divided into four groups of eight. Dogs were experimentally inoculated with protoscolices on Day - 28 for E. granulosus studies and on Day - 18 or - 20 for E. multilocularis studies. Credelio Quattro, placebo, praziquantel, or lotilaner tablets were administered orally at the lower half of the dosage range on Day 0. Efficacy was calculated based on the number of worms recovered at necropsy, 4 or 5 days post-treatment, in the treated group compared to the control.

resultsCredelio Quattro was well tolerated in all dogs. Based on geometric mean worm counts, Credelio Quattro was 100% effective against both E. granulosus and E. multilocularis.

conclusionsCredelio Quattro administered once orally at the minimum dosages of 20 mg/kg of lotilaner, 0.02 mg/kg of moxidectin, 5.0 mg/kg of praziquantel and 5.0 mg/kg of pyrantel was safe and effective for the treatment and control of adult E. granulosus and E. multilocularis in dogs.

Indexed as

AnthelminticsDog DiseasesEchinococcosisEchinococcus granulosusEchinococcus multilocularisAnimalsDogsDrug CombinationsFemaleMacrolidesMaleOxazolesPraziquantelPyrantelTabletsThiophenesAnthelminticsDrug CombinationslotilanerMacrolidesmoxidectinOxazolesPraziquantelPyrantelTabletsThiophenesCestodeEchinococcus granulosusEchinococcus multilocularisEfficacyPraziquantel

Identifiers

PMID40065412
PMCPMC11895180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.